Study S003224

Safety and Efficacy of Once-weekly Subcutaneous and Once-daily Oral NNC0487-0111 in Participants With Type 2 Diabetes - a Dose Finding Study

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06542874
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 448
Start: 2024-08-07
Primary completion: 2025-10-01
Lead sponsor: Novo Nordisk A/S
Conditions: Type 2 Diabetes (T2D)
Interventions: DRUG:NNC0487-0111 subcutanous; DRUG:Placebo (NNC0487-0111 subcutanous); DRUG:NNC0487-0111 oral; DRUG:Placebo (NNC0487-0111 oral)
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1296-9708; OTHER:2023-509412-28; NIH:2023

Registered primary outcomes

Change in HbA1c [From baseline (week 0) to end of treatment (week 36)]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0020979	Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial. Mora P, Lancet (London, England)	2026	Randomized trial	PMID 42532080 DOI	cites ClinicalTrials.gov:NCT06542874; registry reference DERIVED:42532080
R0021369	Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial. Mora P, Lancet (London, England)	2026	Randomized trial	PMID 42532079 DOI	cites ClinicalTrials.gov:NCT06542874; registry reference DERIVED:42532079